|
Résultats pour
brevets
1.
|
PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR CORONAVIRUS INFECTION COMPRISING TETRAARSENIC HEXOXIDE
Numéro d'application |
17926480 |
Statut |
En instance |
Date de dépôt |
2021-04-08 |
Date de la première publication |
2023-06-15 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Kim, Seong Jin
- Lyoo, Kwang Soo
- Yang, Kyung Min
- Wu, Zhaoyan
- Son, Min Jung
- Pang, Kyoungwha
|
Abrégé
Disclosed herein is a pharmaceutical composition comprising tetraarsenic hexoxide as an active ingredient. Having excellent antiviral activity against coronaviruses, the pharmaceutical composition can be advantageously applied to the prevention or treatment of coronavirus diseases.
|
2.
|
PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR CORONAVIRUS INFECTION COMPRISING TETRAARSENIC HEXOXIDE
Numéro d'application |
KR2021004451 |
Numéro de publication |
2021/235695 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2021-04-08 |
Date de publication |
2021-11-25 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Kim, Seong Jin
- Lyoo, Kwang Soo
- Yang, Kyung Min
- Wu, Zhaoyan
- Son, Min Jung
- Pang, Kyoungwha
|
Abrégé
The present invention relates to a pharmaceutical composition comprising tetraarsenic hexoxide as an active ingredient, the composition having excellent antiviral activity against coronavirus, and thus being usefully applicable for the prevention or treatment of coronavirus infection.
|
3.
|
Pharmaceutical composition for treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph
Numéro d'application |
16466243 |
Numéro de brevet |
11154530 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-12-04 |
Date de la première publication |
2020-03-05 |
Date d'octroi |
2021-10-26 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
|
4.
|
Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
Numéro d'application |
16467593 |
Numéro de brevet |
11191779 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-12-04 |
Date de la première publication |
2020-01-02 |
Date d'octroi |
2021-12-07 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
|
5.
|
Pharmaceutical composition for preventing or treating brain cancer including crystal polymorph of tetraarsenic hexoxide, and method for preparing same
Numéro d'application |
16461892 |
Numéro de brevet |
10493100 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-09-07 |
Date de la première publication |
2019-10-31 |
Date d'octroi |
2019-12-03 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
6-a), and to a method for preparing same. A composition according to the present invention exhibits excellent cancer cell proliferation inhibition and metastasis inhibition effects, and thus may be usefully used as an anti-cancer agent.
Classes IPC ?
- A61K 33/36 - ArsenicSes composés
- A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
|
6.
|
Pharmaceutical composition for preventing or treating breast cancer including crystalline polymorph of tetraarsenic hexoxide, and method for producing same
Numéro d'application |
16462011 |
Numéro de brevet |
10525079 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-11-17 |
Date de la première publication |
2019-10-31 |
Date d'octroi |
2020-01-07 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
6-a), of tetraarsenic hexoxide is 99% or higher, and to a method for producing the same. The composition of the present invention exhibits excellent effects of inhibiting the proliferation and metastasis of cancer cells, and thus can be usefully used as an anticancer agent.
Classes IPC ?
- A61K 33/36 - ArsenicSes composés
- A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
|
7.
|
COMPOSITION FOR ANIMAL FEED COMPRISING PHLOROTANNIN AS ACTIVE INGREDIENT AND PRODUCT FOR ANIMAL
Numéro d'application |
KR2019001025 |
Numéro de publication |
2019/147044 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2019-01-24 |
Date de publication |
2019-08-01 |
Propriétaire |
HEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Lee, Haeng Woo
- Kim, Seong Ho
- Cheon, Hyun Cheol
- Yun, Jin Suk
- Kang, Moon Seok
|
Abrégé
The present invention relates to a composition for animal feed having antioxidation and anti-inflammatory properties comprising phlorotannin extracted from brown algae and, particularly, to a composition and a product capable of safe applications on a daily basis by means of using raw materials of natural origins and having a function of improvements in the glossiness of fur, stench, odor of feces, color of the feces, and overweightedness.
Classes IPC ?
- A23K 20/121 - Composés hétérocycliques contenant de l’oxygène ou du soufre comme hétéroatome
- A23K 20/147 - Dérivés polymériques, p. ex. peptides ou protéines
- A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
- A23K 20/24 - Composés de métaux alcalino-terreux, p. ex. de magnesium
- A23K 20/20 - Substances inorganiques, p. ex. oligo-éléments
- A23K 20/174 - Vitamines
- A23K 50/40 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les animaux carnivores, p. ex. pour les chats ou les chiens
|
8.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING TETRAARSENIC HEXOXIDE CRYSTALLINE POLYMORPH
Numéro de document |
03044514 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-12-04 |
Date de disponibilité au public |
2018-06-14 |
Date d'octroi |
2021-06-15 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for preventing or treating cancer and a method for producing same, the composition comprising tetraarsenic hexoxide in which the content of tetraarsenic hexoxide crystalline polymorph a (As4O6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
|
9.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER, COMPRISING TETRAARSENIC HEXOXIDE CRYSTALLINE POLYMORPH
Numéro de document |
03044519 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-12-04 |
Date de disponibilité au public |
2018-06-14 |
Date d'octroi |
2021-06-15 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for preventing or treating liver cancer and a method for producing same, the composition comprising tetraarsenic hexoxide in which the content of tetraarsenic hexoxide crystalline polymorph a (As4O6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
|
10.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING TETRAARSENIC HEXOXIDE CRYSTALLINE POLYMORPH
Numéro d'application |
KR2017014082 |
Numéro de publication |
2018/105972 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-12-04 |
Date de publication |
2018-06-14 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for preventing or treating cancer and a method for producing same, the composition comprising tetraarsenic hexoxide in which the content of tetraarsenic hexoxide crystalline polymorph a (As4O6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
|
11.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER CANCER, COMPRISING TETRAARSENIC HEXOXIDE CRYSTALLINE POLYMORPH
Numéro d'application |
KR2017014083 |
Numéro de publication |
2018/105973 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-12-04 |
Date de publication |
2018-06-14 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for preventing or treating liver cancer and a method for producing same, the composition comprising tetraarsenic hexoxide in which the content of tetraarsenic hexoxide crystalline polymorph a (As4O6-a) is 99% or more. The composition of the present invention exhibits an excellent cancer cell proliferation inhibition effect and thus can be useful as an anticancer drug.
|
12.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN CANCER INCLUDING CRYSTAL POLYMORPH OF TETRAARSENIC HEXOXIDE, AND METHOD FOR PREPARING SAME
Numéro d'application |
KR2017009820 |
Numéro de publication |
2018/093029 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-09-07 |
Date de publication |
2018-05-24 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition which is for preventing or treating brain cancer and includes at least 99% of a crystal polymorph of tetraarsenic hexoxide a(As406-a), and to a method for preparing same. A composition according to the present invention exhibits excellent cancer cell proliferation inhibition and metastasis inhibition effects, and thus may be usefully used as an anti-cancer agent.
|
13.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BREAST CANCER INCLUDING CRYSTALLINE POLYMORPH OF TETRAARSENIC HEXOXIDE, AND METHOD FOR PRODUCING SAME
Numéro d'application |
KR2017013148 |
Numéro de publication |
2018/093215 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-11-17 |
Date de publication |
2018-05-24 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for preventing or treating breast cancer which includes tetraarsenic hexoxide in which a crystalline polymorph a(As4O6-a), of tetraarsenic hexoxide is 99% or higher, and to a method for producing the same. The composition of the present invention exhibits excellent effects of inhibiting the proliferation and metastasis of cancer cells, and thus can be usefully used as an anticancer agent.
|
14.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BRAIN CANCER INCLUDING CRYSTAL POLYMORPH OF TETRAARSENIC HEXOXIDE, AND METHOD FOR PREPARING SAME
Numéro de document |
03043145 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-09-07 |
Date de disponibilité au public |
2018-05-24 |
Date d'octroi |
2021-11-09 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition which is for preventing or treating brain cancer and includes at least 99% of a crystal polymorph of tetraarsenic hexoxide a(As406-a), and to a method for preparing same. A composition according to the present invention exhibits excellent cancer cell proliferation inhibition and metastasis inhibition effects, and thus may be usefully used as an anti-cancer agent.
|
15.
|
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BREAST CANCER INCLUDING CRYSTALLINE POLYMORPH OF TETRAARSENIC HEXOXIDE, AND METHOD FOR PRODUCING SAME
Numéro de document |
03043153 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-11-17 |
Date de disponibilité au public |
2018-05-24 |
Date d'octroi |
2021-11-02 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for preventing or treating breast cancer which includes tetraarsenic hexoxide in which a crystalline polymorph a(As4O6-a), of tetraarsenic hexoxide is 99% or higher, and to a method for producing the same. The composition of the present invention exhibits excellent effects of inhibiting the proliferation and metastasis of cancer cells, and thus can be usefully used as an anticancer agent.
|
16.
|
PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS, CONTAINING TETRAARSENIC OXIDE
Numéro d'application |
KR2017009819 |
Numéro de publication |
2018/088682 |
Statut |
Délivré - en vigueur |
Date de dépôt |
2017-09-07 |
Date de publication |
2018-05-17 |
Propriétaire |
CHEMAS CO., LTD. (République de Corée)
|
Inventeur(s) |
- Bae, Ill Ju
- Lian, Zenglin
|
Abrégé
The present invention relates to a pharmaceutical composition for inhibiting cancer metastasis, containing tetraarsenic oxide (As4O6). As4O6 has been confirmed to inhibit cancer cell infiltration and migration mediated by an epidermal growth factor receptor (EGFR) and a human epidermal growth factor receptor-2 (HER-2) and to have an inhibitory effect superior to that of As2O3, and thus is expected to be usable as a therapeutic agent for preventing or inhibiting cancer metastasis.
Classes IPC ?
- A61K 33/36 - ArsenicSes composés
- A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
|
|